Recherche clinique

La CNO participe à la recherche clinique dans un large éventail de maladies neurologiques. Nous croyons important de contribuer au développement de nouvelles thérapies et d’enrichir les connaissances en neurosciences et en médecine.

Nous travaillons à rendre les fauteuils roulants obsolètes.

Clinical Research

Contributing to the development of new therapies. From intravenous treatments, to neuro-physiotherapy and Transcranial Magnetic Stimulation, our breadth of services allows us to not only provide better tailored solutions, but also to buttress our various expertise with clinical trials and unique research studies.

Areas of Research

Accessing cutting edge therapies.

Why clinical research?

At CNO, research and clinical practice go hand in hand.

We continuously participate in a number of clinical trials aiming to create better treatments for a variety of diseases: Multiple Sclerosis, Stroke, Parkinson’s, Alzheimer’s and Glioblastoma Multiforme (GBM). Our participation allows us to offer many treatments long before they become available to a majority of specialists, giving patients an opportunity to choose from a wide range of care that, while experimental in nature, may possibly be more effective.

Cutting-edge treatments aren’t the only reason we conduct clinical trials, nor are they the only reason patients decide to participate. Our involvement gives us the opportunity to develop better protocols and to help advance the treatments themselves. When it comes to neurological diseases, large strides have been made in recent years; results that would have been impossible without the participation of doctors, nurses and patients.

Research complements our therapeutic approach.

Francois Jacques, Neurologist, Founder.

Current MS Trials

Phase 1 Research

Developing new treatments.

When new therapies are developed, they need to be tested by healthy individuals. We are establishing phase 1 research capabilities and are looking for people interested in participating in this important phase of clinical research. If you or someone you know is interested in participating in phase 1 research protocols please get in touch.

Research is at the Core of Our Practice

We participate in a number of clinical trials aiming to create advancements for the treatment of Multiple Sclerosis, Stroke, Parkinson’s, Alzheimer’s and Glioblastoma Multiforme (GBM). Our participation allows us to offer many treatments long before they become available to a majority of specialists, giving patients an opportunity to choose from a wide range of care that, while experimental in nature, may possibly be more effective. Cutting edge treatments aren’t the only reason we conduct clinical trials, nor are they the only reason patients decide to participate. Our involvement gives us the opportunity to develop better protocols and, most importantly, to help advance the treatments themselves. When it comes to Neurological diseases, large strides have been made in recent years; results that would have been impossible without the participation of Doctors, Nurses and, most of all, patients.

Neurogym and Clinical Research

Until recently, there were few, if any, evidence based neurological treatments beyond that of the pharmacological variety. This is changing. Thanks to our NeuroGym, we now offer neuro-physiotherapy and custom designed training equipment to complement pharmacological approaches. The notion that specific physical exercises can help slow disease progression and speed up recovery, though often intuitively applied in other fields, is nonetheless novel to neurology. This gives us the opportunity to conduct cutting-edge evidence based research concerning the efficacy of combined treatment options. Best of all, it also gives patients the opportunity to take charge of their recovery.
Click here to find out more about NeuroGym.

In accordance with our mandate to provide the most comprehensive neurological care possible, we were the first to introduce Transcranial Magnetic Stimulation (“Mag-Stim“) to the Gatineau region. Mag-Stim’s efficacy in treating neurological issues is now well documented, and its use is no longer uncommon in the Ottawa-Gatineau region’s psychiatric centers.
Click here to find out more about Magnetic Stimulation.

That being said, we continue to be at the forefront of this treatment’s evolution; consistently developing new and better protocols thanks to our Neuro-Navigation, which allows us to actively and accurately plot the areas of the brain we stimulate with greater precision. Like every other neurological tool at Clinique Neuro-Outaouais, this allows us to not only research better treatments but also to provide a new level of customized care.

The Future

In the short term, it is our ability to combine treatments that provide the most avenue for increased efficacy; a complement to ongoing clinical research which promises gradual long term improvement. At Clinique Neuro-Outaouais, we’re excited to have had evidence based success in improving patient care. We invite you to read our blog, and to contact us in order to learn more about our ongoing research trials and the range of our services.

Pourquoi la recherche clinique?

À la CNO, la recherche et la pratique clinique vont de pair.

Nous participons de façon continue à plusieurs essais cliniques visant à mettre au point de meilleurs traitements pour diverses maladies : sclérose en plaques, AVC, maladie de Parkinson, maladie d’Alzheimer et glioblastome multiforme (GBM). Notre participation nous permet d’offrir de nombreux traitements bien avant qu’ils ne deviennent accessibles à la majorité des spécialistes, donnant ainsi aux patients la possibilité de choisir parmi un éventail de soins qui, bien qu’expérimentaux, peuvent s’avérer plus efficaces. Les traitements de pointe ne sont pas la seule raison pour laquelle nous menons des essais cliniques, ni la seule raison pour laquelle les patients choisissent d’y participer. Notre implication nous permet d’améliorer les protocoles et de faire progresser les traitements eux-mêmes. En neurologie, des avancées majeures ont été réalisées ces dernières années; elles auraient été impossibles sans la participation conjointe des médecins, des infirmières et des patients.

« La recherche complète notre approche thérapeutique. »

— François Jacques, neurologue, fondateur

Sclérose en plaques

Au cours des dernières décennies, le domaine de la SEP a connu une expansion rapide des nouvelles thérapies. Depuis 25 ans, la CNO participe au développement de la plupart des nouveaux traitements pour la SEP. Nous continuons d’y contribuer et demeurons à l’avant-garde de la recherche clinique sur la SEP.

Myasthénie grave

La dernière décennie a transformé le paysage thérapeutique de la myasthénie grave. De nouveaux traitements aux mécanismes novateurs — déplétion des lymphocytes B, inhibition du complément, blocage du récepteur néonatal Fc — sont maintenant disponibles et offrent la perspective de rémissions prolongées.

Maladie de Parkinson

La recherche sur la maladie de Parkinson a accompli d’immenses progrès au cours des dernières décennies : meilleure compréhension des mécanismes sous-jacents, amélioration des traitements symptomatiques et interventions visant à ralentir ou stopper la progression de la maladie.

Neuropathie motrice multifocale

La neuropathie motrice multifocale (NMM) est une maladie auto-immune rare touchant les nerfs moteurs périphériques. Elle se manifeste par une faiblesse asymétrique, indolore et lentement progressive des mains et/ou des jambes, sans perte sensitive.

Sclérose latérale amyotrophique (SLA)

La SLA est une maladie neurodégénérative rare qui touche les systèmes nerveux central et périphérique, avec une incidence estimée de 1 à 3 cas par 100 000 personnes par année.

Maladie d’Alzheimer

La maladie d’Alzheimer est une affection cérébrale progressive et éventuellement fatale, responsable de 60 à 80 % des cas de démence. Les processus pathologiques débutent des décennies avant les premiers symptômes, d’où l’importance du dépistage et d’interventions précoces.

Polyradiculonévrite inflammatoire démyélinisante chronique (PIDC)

La PIDC est une maladie auto-immune qui atteint le système nerveux périphérique.

Glioblastome multiforme

Le glioblastome multiforme est la forme la plus fréquente et la plus agressive des tumeurs cérébrales malignes primaires.